172 results
8-K/A
EX-99.2
NEO
Neogenomics Inc.
1 Sep 21
Consolidated financial statements
4:34pm
Operating expenses:
General and administrative
Research and development
Sales and marketing
Total operating expenses
(LOSS) INCOME FROM OPERATIONS … and administrative
Research and development
Sales and marketing
Total operating expenses
LOSS FROM OPERATIONS
Interest expense, net
Other (income) expense
8-K/A
EX-99.1
NEO
Neogenomics Inc.
1 Sep 21
Consolidated financial statements
4:34pm
Research and development expenses
Administrative expenses
Operating loss
Foreign currency losses
Interest receivable and similar income
Loss before taxation … volume, data access or biopharmaceutical research and development services over a defined period. The Company recognizes revenue upon delivery
8-K
EX-99.2
NEO
Neogenomics Inc.
11 Jan 12
NeoGenomics Enters Into Exclusive Worldwide Licensing Agreement
12:00am
the appointment of Dr. Maher Albitar as Chief Medical Officer and Director of Research and Development.
From 2003 to 2010, Dr. Albitar served as the Medical … Director for Hematopathology and Oncology, and Chief of Research and Development, for Quest Diagnostics Nichols Institute. He was responsible
8-K
EX-10.3
txg63
11 Jan 12
NeoGenomics Enters Into Exclusive Worldwide Licensing Agreement
12:00am
8-K
EX-10.2
n7y9t0a8zdbbx661
11 Jan 12
NeoGenomics Enters Into Exclusive Worldwide Licensing Agreement
12:00am